New CEO Revamps Top Team, Specialty Care Business At Sobi

The new CEO of Swedish Orphan Biovitrum AB (Sobi), Guido Oelkers, has hit the ground running at the European rare diseases company, announcing a new executive committee and a newly established business area, specialty care, along with an up-tick in the company's financial guidance for the year, driven by the sales growth of its recently launched long-acting hemophilia products.

Oelkers, who took up his position in the middle of May, said he also wanted to build up Sobi's late-stage product pipeline, by searching for assets that would complement the company's own research, speaking during a